# A Real World Study of Anti-PD-1/PD-L1 Antibodies for the Treatment of Advanced Solid Tumors

> **NCT03787953** · — · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 400 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** Anti-PD-1/PD-L1 antibodies

## Key facts

- **NCT ID:** NCT03787953
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-30
- **Primary completion:** 2019-09-30
- **Final completion:** 2019-09-30
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2019-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03787953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03787953, "A Real World Study of Anti-PD-1/PD-L1 Antibodies for the Treatment of Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03787953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*